Some targeted systemic therapies have demonstrated evidence of activity in the brain-specifically in melanoma, lung cancers, and breast cancers-and these agents warrant further study in clinical trials.
Priscilla K. Brastianos, MD
Advertisement
Articles by Priscilla K. Brastianos, MD
Advertisement
Latest Updated Articles
- Management of Brain Metastases in the Era of Targeted and Immunomodulatory Therapies
Published: April 15th 2015 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma
2
FDA Grants Fast Track Designation to MT-125 in Glioblastoma
3
HDP-101 Receives FDA Fast Track Designation in Multiple Myeloma
4
FDA Accepts NDA for New Nilotinib Formulation in CML
5
